Neuromod Devices raises $6.2 mln

Neuromod Devices Ltd. said Tuesday that it raised 5.5 million euros (US$6.2 million) in Series A funding from Fountain Healthcare Partners. Dublin-based Neuromod specializes in treatment of chronic tinnitus. PRESS RELEASE DUBLIN–(BUSINESS WIRE)–Neuromod Devices Limited (Neuromod), an Irish medical device company specialising in the treatment of chronic tinnitus, announces that it has raised €5.5 million ($6.2million) in Series A Funding from international life sciences venture capital fund Fountain Healthcare Partners. The investment will be used to further enhance scientific and clinical understanding of its bi-modal neuromodulation device, mutebutton®, and commence US clinical trials. The international launch of mutebutton® is targeted for 2018. This investment marks a significant milestone for Neuromod and brings the total raised by the company to-date to over €8 million ($9 million). As part of the Series A financing, Dr Manus Rogan of Fountain Healthcare Partners will join the Board of Directors of Neuromod. Neuromod’s non-invasive mutebutton® device uses bi-modal neuromodulation via simultaneous auditory stimulation in the ear and sensory stimulation on the tongue to promote positive changes in neuroplasticity in parts of the brain implicated in tinnitus. Recent developments in international tinnitus research indicate that neuromodulation is emerging as one of the most promising therapies for certain forms tinnitus. Neuromod will use the proceeds from the investment to advance dose optimisation and patient sub-typing research and commence US clinical trials. The mutebutton® device received a medical device CE mark in Europe in October 2014 and a US Patent for its technology in September 2015. About 250 million people worldwide experience chronic tinnitus on a daily basis. It manifests as an illusory sound with no external source or origin. Chronic tinnitus can have a severe impact on a patient’s quality of life, with documented secondary symptoms including anxiety, insomnia, headaches and depression, resulting in repeat visits to GP’s, ENT surgeons and Clinical Audiologists. Dr Ross O’Neill, Founding CEO of Neuromod commented, “Neuromod is delighted to announce this investment, which will help us to advance our unique chronic tinnitus treatment technology. As an emerging company we welcome the support and knowledge offered to us from partnering with an experienced international life sciences venture capital fund such as Fountain Healthcare Partners. We are also particularly grateful for the ongoing support we have received from our manufacturing partners, M&M Qualtech and Molex, and from Enterprise Ireland, which enable innovative Irish companies, like Neuromod, to grow and succeed on the international stage.” Dr Manus Rogan, Co-Founder and Managing Partner at Fountain Healthcare Partners added. “Neuromod is an exciting company, with the potential to offer a superior treatment to and improve the quality of life of the millions of patients suffering with chronic tinnitus. The company has a proprietary neuromodulation technology, promising clinical results and a highly committed team. Neuromodulation is a key area of interest for Fountain Healthcare and chronic tinnitus is a poorly served global market opportunity with relatively little competition. We are investing in Neuromod to help build a credible and sustainable business in tinnitus with prospects for strong future growth.”

More:
Neuromod Devices raises $6.2 mln